Cargando…
Unusual Presentation of an Uncommon Malignancy: A 74-Year-Old Woman with Aggressive Fibromatosis of the Large Intestine Presenting as a Liver Mass and the Therapeutic Management
Patient: Female, 74-year-old Final Diagnosis: Desmoid tumor Symptoms: Abdominal pain • dairrhea Clinical Procedure: — Specialty: Gastroenterology and Hepatology • Oncology • Pathology • Surgery OBJECTIVE: Rare disease BACKGROUND: Desmoid tumors are a fibroblastic proliferation of soft tissues, with...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578500/ https://www.ncbi.nlm.nih.gov/pubmed/37812585 http://dx.doi.org/10.12659/AJCR.939862 |
Sumario: | Patient: Female, 74-year-old Final Diagnosis: Desmoid tumor Symptoms: Abdominal pain • dairrhea Clinical Procedure: — Specialty: Gastroenterology and Hepatology • Oncology • Pathology • Surgery OBJECTIVE: Rare disease BACKGROUND: Desmoid tumors are a fibroblastic proliferation of soft tissues, with an extreme inclination for local dissemination and recurrence. Surgical excision is the usual treatment choice, with data regarding pharmaceutical treatment being scarce. CASE REPORT: A 74-year-old female patient was admitted to “Laikon” General Hospital of Athens, Greece presenting with acute kidney injury secondary to diarrhea. The ultrasound, CT, and abdominal MRI performed showed a 12×6×10 cm tumorous liver lesion. Biopsy of the lesion revealed loosely organized, mesenchymal tissue with spindle cells, and myxoid stroma. Immunochemistry was positive for SMA and b-catenin. Right hemicolectomy was performed with tumor-free surgical margins (R0 resection) and tamoxifen was initiated. Six months after the last MRI (3 months after the use of tamoxifen), a follow-up MRI was performed. The tumor had increased to 14.2×11×12.3 cm, and at the next follow-up it had grown to 20.3×19 cm maximal dimensions; no new metastases were found. The patient received sorafenib and pazopanib. Our patient had PFS with sorafenib for more than 2 years and remained in a good performance status (ECOG 1). For Pazopanid, the median PFS for this treatment option was 6.5 months. CONCLUSIONS: The results were good and show a promising method for the treatment of this rare but severe malignancy. |
---|